Proton Pump Inhibitors Diminish Barrett's Esophagus Length: Our Experience
DOI:
https://doi.org/10.3889/oamjms.2018.232Keywords:
Proton pump inhibitor, Endoscopy, Barrett’s oesophagus, Squamous islandsAbstract
AIM: Our main objectives were to evaluate the influence of two-year proton pump inhibitors (PPI) therapy in patients with Barrett's oesophagus on its length, in both types, short and long segment.
METHODS: In this single-centre, prospective interventional controlled study were analysed data collected prospectively over two years from patients with Barrett's oesophagus diagnosed by endoscopy. Patients who received continuous proton pump inhibitors (PPI) for 2 years. At each patient visit symptoms were recorded, and at each endoscopy, the length of Barrett's oesophagus (BE) was measured. Biopsies were taken along the length of the oesophagus at intervals of 1 cm. In total, 50 patients with Barrett's oesophagus were included in the study: 10 of whom had long-segment Barrett's oesophagus, and 40 patients had short-segment Barrett's oesophagus. The mean number of endoscopies performed was 3 per patient.
RESULTS: The length of Barrett's esophagus (BE) was influenced by PPI therapy: Circumferential extension in BE patients short-segment Barrett's esophagus (SSBE) (before treatment was 1.5 cm and after treatment was 0.8 cm Maximum proximal extension in SSBE group before treatment was 2.3 cm (SD ± 1.1 cm), and 1.1 cm (SD ± 0.9 cm), respectively. Squamous islands were detected in 25% of patients examined after 2 years on PPIs.
CONCLUSIONS: PPIs achieve a reduction to the length of Barrett's oesophagus, in both types, and the development of squamous islands is commonly associated with their use.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008; 103:788-797. https://doi.org/10.1111/j.1572-0241.2008.01835.xPMid:18341497
Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut. 2006; 55:442. https://doi.org/10.1136/gut.2005.083600 PMid:16531521 PMCid:PMC1856188
Kerkhof M, Steyerberg EW, Kusters JG, Kuipers EJ, Siersema PD. Predicting presence of intestinal metaplasia and dysplasia in columnar-lined esophagus: a multivariate analysis. Endoscopy. 2007; 39:772-778. https://doi.org/10.1055/s-2007-966737 PMid:17703384
Van Baal, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, van Deventer SJ, et al. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology. 2005; 129:1274-1281. https://doi.org/10.1053/j.gastro.2005.07.026 PMid:16230080
Kelty CJ, Gough MD, Van Wyk Q, Stephenson TJ, Ackroyd R. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007; 42:1271-1274. https://doi.org/10.1080/00365520701420735 PMid:17852872
Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y. et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006; 131:1392-1399. https://doi.org/10.1053/j.gastro.2006.08.032 PMid:17101315
Wang KK, Sampliner RE. Practice guidelines Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. American Journal of Gastroenterology, 2008. https://doi.org/10.1111/j.1572-0241.2008.01835.x
Weinstein MW. The prevention and treatment of dysplasia in gastroesophageal reflux disease: The results and the challenges ahead. J Gastroenterol Hepatol. 2002; 17:S113-S124. https://doi.org/10.1046/j.1440-1746.17.s1.9.x PMid:12000598
Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 1994; 89:1844-1848. PMid:7942680
Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol. 1997; 92:582-585. PMid:9128303
Malesci A, Savarino V, Zentilin P, Belicchi M, Mela GS, Lapertosa G et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc. 1996; 44:700-705. https://doi.org/10.1016/S0016-5107(96)70055-X
Srinivasan R, Katz PO, Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther. 2001; 15:519-524. https://doi.org/10.1046/j.1365-2036.2001.00958.x PMid:11284781
Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Gastroenterology. 1999; 116:277-85. https://doi.org/10.1016/S0016-5085(99)70123-X
Csendes A, Smok G, Burdiles P, Korn O, Gradiz M, Rojas J, Recio M. Prevalence of intestinal metaplasia according to the length of specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis Esophagus. 2003; 16:24-8. https://doi.org/10.1046/j.1442-2050.2003.00284.x PMid:12581250
Hanna S, Rastogi A, Weston AP, Totta F, Schmitz R, Mathur S, McGregor D, Cherian R, Sharma P. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol. 2006; 101:1416-20. https://doi.org/10.1111/j.1572-0241.2006.00631.x PMid:16863541
Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004; 127(1):310-30. https://doi.org/10.1053/j.gastro.2004.04.010 PMid:15236196
Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus, British Society of Gastoenterology (BSG), August 2005.
Spechler SJ. The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. J Clin Gastroenterol. 2003; 36:S2–S5; discussion S26-S28.
Garrido SA, Guerrero Igea FJ, Lepe Jimenez JA, Perianes HC. Clinical features and endoscopic progression of gastroesophageal reflux disease. Rev Esp Enferm Dig. 2003; 95:712-16.
Odze RD. Barrett esophagus: histology and pathology for the clinician. Nat Rev Gastroenterol Hepatol. 2009; 6:478-490. https://doi.org/10.1038/nrgastro.2009.103 PMid:19581906
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
